The World Health Organization, WHO, Technical Advisory Group has recommended that Ervebo vaccine be prioritised for a randomised clinical trial against Bundibugyo virus disease in the Democratic Republic of Congo.
In a statement, the WHO said the recommendation followed new preliminary animal-study data indicating that Ervebo can provide some cross-protection against Bundibugyo virus disease, particularly to reduce deaths.
It said that the advisory group made the recommendation after reviewing available evidence on the vaccine’s safety, efficacy, availability and feasibility during its third meeting on July 31.
The statement said that WHO convened advisory groups after declaring a Public Health Emergency of International Concern on May 16 over the Bundibugyo virus outbreak.
“Initially, the group advised against using Ervebo outside carefully designed research settings because its effectiveness against Bundibugyo virus disease remained uncertain.
Also Read: WHO raise the alarm on DRC Ebola spread
“Ervebo is currently the only licensed Ebola vaccine, but it was developed specifically against Ebola virus disease caused by Ebola Zaire virus,” it said.
The WHO noted that the experts said there were no identified safety concerns with Ervebo for use among contacts of confirmed cases during a Bundibugyo virus disease outbreak.
The group however stressed that Ervebo’s effectiveness against Bundibugyo disease and transmission has not yet been established and requires evaluation through clinical research.
According to it, a vaccine specifically developed against Bundibugyo virus will remain the preferred option, although preliminary data on such candidates are currently unavailable.
It said that the advisory group also emphasised the need to facilitate large-scale vaccine production and access if future evidence demonstrates sufficient efficacy to protect affected populations.
NAN
